{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018696","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.199484+00:00","generated_at":"2026-06-25T22:16:47.828909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LENSAR Q1 2022 revenue $9.3M (+33% YoY); net loss $6.7M; ALLY 510(k) under FDA review","bullets":["Total revenue $9.3M, up 33% from $7.0M in Q1 2021; 89% from recurring sources.","Procedure volume 38,901, up 38% YoY; product, lease, and service revenue all increased.","Net loss $6.7M ($0.67 per share) vs $5.2M ($0.56) in Q1 2021; R&D expense rose 74% to $4.8M due to ALLY development.","FDA accepted 510(k) for ALLY Adaptive Cataract Treatment System; launch anticipated in 2022 if cleared.","Adjusted EBITDA was ($4.2)M vs ($2.2)M in Q1 2021; stock-based comp $1.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018696","json":"https://secwatch.observer/filing/0001564590-22-018696.json","markdown":"https://secwatch.observer/filing/0001564590-22-018696.md","text":"https://secwatch.observer/filing/0001564590-22-018696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022018696/0001564590-22-018696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022018696/lnsr-8k_20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:16:47.828909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}